Bristol Myers (BMY) Squibb announced that the U.S. Food and Drug Administration has accepted and granted priority review to the supplemental Biologics License Application for Opdivo in combination with doxorubicin, vinblastine and dacarbazine for adult and pediatric patients with previously untreated Stage III or IV classical Hodgkin Lymphoma. The FDA assigned a Prescription Drug User Fee Act goal date of April 8, 2026. The FDA filing acceptance is based on the Phase 3 SWOG S1826 study, evaluating Opdivo in combination with AVD for adult and pediatric patients with previously untreated Stage III or IV cHL.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Bristol Myers raises quarterly dividend 1.6% to 63c per share
- Bristol Myers price target raised to $53 from $50 at HSBC
- Trump Weekly: President approves U.S. manufacturing of ‘tiny cars’
- Bristol Myers’ Breyanzi approved by FDA as CAR-T therapy for MZL
- FDA shift in drug study requirements sends trial runners lower